Long term treatment with adagrasib for solid tumor patients
Part of Cancer clinical trials.
This trial allows people with solid tumors who are already benefiting from the study drug adagrasib in an earlier Mirati study to continue getting it for the long term. It’s for people whose doctors see ongoing benefit and who still meet the safety rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been in an earlier Mirati trial for adagrasib and be getting the study drug now.
- Your doctor must see that you are still benefiting from the treatment (not just finished or progressed).
- If you were assigned female at birth, you must either not be able to get pregnant or agree to use effective birth control.
- You cannot be joining if you were already taken off the earlier trial for safety or if the cancer was getting worse while on that treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called IBI3020 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for these patients.
This early-stage trial tests a new investigational drug (ADG126) combined with pembrolizumab in people with advanced or metastatic solid tumors. It aims to find a safe dose and see whether the combination can shrink tumors.
This trial tests a new drug, IMGS-001, in people with advanced solid tumors that have grown back or not responded to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
This trial tests a new investigational drug, BMS-986488, alone or with another drug (adagrasib), for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and works against certain cancers.
This trial tests MPB-1734, a new study drug, in adults with advanced solid tumors that can’t be removed and for which standard treatment has stopped working. It aims to find out how safe it is and whether it can shrink or control the cancer.
This study is for people who are already taking the targeted therapy sotorasib (with or without another drug called panitumumab) in an Amgen clinical trial and are still doing well. It lets you keep receiving the same treatment after your original study ends, so you don't have to stop a medicine that is working for you.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.